FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386083921> ?p ?o ?g. }

• W4386083921 abstract "This meta-analysis aimed to evaluate the efficacy and safety/tolerability of imeglimin, a novel oral antihyperglycemic agent, administered as monotherapy and adjunctive therapy in patients with type 2 diabetes mellitus.Parallel-group randomized controlled trials comparing imeglimin with placebo in adults with type 2 diabetes mellitus were included. Risk ratios or weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated using random effects models. The primary outcome for efficacy was the change in glycated hemoglobin (HbA1c). Secondary outcomes included other efficacy-related outcomes, specific adverse events, and changes in body weight and lipid parameters.Nine randomized controlled trials (n = 1,655) were included. When analyzed by dose, there was a significant difference in glycated hemoglobin (%) between imeglimin monotherapy and placebo at doses >1,000 mg twice daily (1,000 mg: studies N = 3, patients n = 517, WMD = -0.714, P < 0.001; 1,500 mg: N = 5, n = 448, WMD = -0.531, P = 0.020; 2,000 mg: N = 1, n = 149, WMD = -0.450, P = 0.005). Imeglimin adjunctive therapy significantly improved glycated hemoglobin over placebo at doses of 1,000 mg (N = 1, n = 214, WMD = -0.600, P < 0.001) and 1,500 mg (N = 2, n = 324, WMD = -0.576, P < 0.001). Subgroup analysis of the primary outcome showed that imeglimin was effective regardless of chronic kidney disease category, with studies carried out in Japan and in patients with lower body mass index showing a trend toward improved imeglimin efficacy. There were no significant differences between imeglimin and placebo in the risk of all-cause discontinuation and the proportion of patients who presented with at least one adverse event.Imeglimin is efficacious, safe, and well tolerated as monotherapy and adjunctive therapy." @default.
• W4386083921 created "2023-08-24" @default.
• W4386083921 creator A5036190568 @default.
• W4386083921 creator A5043895658 @default.
• W4386083921 creator A5066606669 @default.
• W4386083921 creator A5068813241 @default.
• W4386083921 creator A5088439699 @default.
• W4386083921 date "2023-08-23" @default.
• W4386083921 modified "2023-09-26" @default.
• W4386083921 title "Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials" @default.
• W4386083921 cites W1998401806 @default.
• W4386083921 cites W2001956441 @default.
• W4386083921 cites W2025436379 @default.
• W4386083921 cites W2098923148 @default.
• W4386083921 cites W2107328434 @default.
• W4386083921 cites W2120741242 @default.
• W4386083921 cites W2126930838 @default.
• W4386083921 cites W2134293572 @default.
• W4386083921 cites W2146462191 @default.
• W4386083921 cites W2150327210 @default.
• W4386083921 cites W2165229130 @default.
• W4386083921 cites W2515784845 @default.
• W4386083921 cites W2809463321 @default.
• W4386083921 cites W2899736836 @default.
• W4386083921 cites W2983229458 @default.
• W4386083921 cites W2992666626 @default.
• W4386083921 cites W3017104819 @default.
• W4386083921 cites W3033248843 @default.
• W4386083921 cites W3108349261 @default.
• W4386083921 cites W3118615836 @default.
• W4386083921 cites W3127703453 @default.
• W4386083921 cites W3129287464 @default.
• W4386083921 cites W3131822672 @default.
• W4386083921 cites W3187356784 @default.
• W4386083921 cites W3200098731 @default.
• W4386083921 cites W3202296806 @default.
• W4386083921 cites W3210422515 @default.
• W4386083921 cites W4206947837 @default.
• W4386083921 cites W4212849797 @default.
• W4386083921 cites W4214521725 @default.
• W4386083921 cites W4220891127 @default.
• W4386083921 cites W4289520118 @default.
• W4386083921 cites W4298004522 @default.
• W4386083921 cites W4306163784 @default.
• W4386083921 cites W4316035430 @default.
• W4386083921 doi "https://doi.org/10.1111/jdi.14070" @default.
• W4386083921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37610062" @default.
• W4386083921 hasPublicationYear "2023" @default.
• W4386083921 type Work @default.
• W4386083921 citedByCount "0" @default.
• W4386083921 crossrefType "journal-article" @default.
• W4386083921 hasAuthorship W4386083921A5036190568 @default.
• W4386083921 hasAuthorship W4386083921A5043895658 @default.
• W4386083921 hasAuthorship W4386083921A5066606669 @default.
• W4386083921 hasAuthorship W4386083921A5068813241 @default.
• W4386083921 hasAuthorship W4386083921A5088439699 @default.
• W4386083921 hasBestOaLocation W43860839211 @default.
• W4386083921 hasConcept C126322002 @default.
• W4386083921 hasConcept C134018914 @default.
• W4386083921 hasConcept C142724271 @default.
• W4386083921 hasConcept C168563851 @default.
• W4386083921 hasConcept C187960798 @default.
• W4386083921 hasConcept C197934379 @default.
• W4386083921 hasConcept C204787440 @default.
• W4386083921 hasConcept C27081682 @default.
• W4386083921 hasConcept C2777180221 @default.
• W4386083921 hasConcept C2777538456 @default.
• W4386083921 hasConcept C2778375690 @default.
• W4386083921 hasConcept C2780221984 @default.
• W4386083921 hasConcept C2910068830 @default.
• W4386083921 hasConcept C44249647 @default.
• W4386083921 hasConcept C555293320 @default.
• W4386083921 hasConcept C71924100 @default.
• W4386083921 hasConcept C82789193 @default.
• W4386083921 hasConcept C90924648 @default.
• W4386083921 hasConcept C95190672 @default.
• W4386083921 hasConceptScore W4386083921C126322002 @default.
• W4386083921 hasConceptScore W4386083921C134018914 @default.
• W4386083921 hasConceptScore W4386083921C142724271 @default.
• W4386083921 hasConceptScore W4386083921C168563851 @default.
• W4386083921 hasConceptScore W4386083921C187960798 @default.
• W4386083921 hasConceptScore W4386083921C197934379 @default.
• W4386083921 hasConceptScore W4386083921C204787440 @default.
• W4386083921 hasConceptScore W4386083921C27081682 @default.
• W4386083921 hasConceptScore W4386083921C2777180221 @default.
• W4386083921 hasConceptScore W4386083921C2777538456 @default.
• W4386083921 hasConceptScore W4386083921C2778375690 @default.
• W4386083921 hasConceptScore W4386083921C2780221984 @default.
• W4386083921 hasConceptScore W4386083921C2910068830 @default.
• W4386083921 hasConceptScore W4386083921C44249647 @default.
• W4386083921 hasConceptScore W4386083921C555293320 @default.
• W4386083921 hasConceptScore W4386083921C71924100 @default.
• W4386083921 hasConceptScore W4386083921C82789193 @default.
• W4386083921 hasConceptScore W4386083921C90924648 @default.
• W4386083921 hasConceptScore W4386083921C95190672 @default.
• W4386083921 hasLocation W43860839211 @default.
• W4386083921 hasLocation W43860839212 @default.
• W4386083921 hasOpenAccess W4386083921 @default.
• W4386083921 hasPrimaryLocation W43860839211 @default.
• W4386083921 hasRelatedWork W2096190005 @default.

• next